Trade Mark Journal No.2026/015 10 April 2026
WO0000001895066 (5,10,42)
Office of origin: United States of America
Date of International Registration:19 November 2025
Date of designation in the UK:
19 November 2025
International priority date claimed: 18 November 2025
(United States of America)
(99503488)
- Class 5
- Pharmaceutical preparations for the treatment of erythropoietic porphyria (EPP), X-linked protoporphyria (XLPP), genetic diseases and disorders, dermatological diseases and disorders, hematological diseases and disorders, liver diseases and disorders, and photosensitivity.
- Class 10
- Medical tools being devices for diagnosing erythropoietic protoporphyria; medical tools being devices for treating and diagnosing sun exposure.
- Class 42
- Research and development of pharmaceuticals and biologics for the treatment of immunologic disorders, hematologic disorders, anemia disorders, oncologic disorders and renal disorders; none of the foregoing offered in connection with treatment of diseases or disorders relating to spinal discs; scientific research and development in the field of sun exposure and related disease risk; research and development of pharmaceuticals, biologic preparations and medicines in the field of sun exposure and related disease risk; medical research and development in the field of sun exposure and related disease risk; conducting surveys and questionnaires being surveys to detect sun exposure and related disease risk.
Disc Medicine, Inc.
Representative: Christina M. Licursi Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston MA 02210-2206, UNITED STATES OF AMERICA